EASL 2023 Audio Recap
Viral Hepatitis Update: CCO Independent Conference Coverage of EASL 2023

Released: July 11, 2023

Tatyana Kushner
Tatyana Kushner, MD, MSCE
Heiner Wedemeyer
Heiner Wedemeyer, MD
Stefan Zeuzem
Stefan Zeuzem, MD

Activity

Progress
1
Course Completed

In this episode, Stefan Zeuzem, MD, discusses new data on viral hepatitis presented at EASL 2023, including:

  • Hepatitis B virus
    • Durability of response with bepirovirsen
    • HBsAg loss with siRNA VIR-2218 combined with either VIR-3434 (novel monoclonal antibody) or pegIFN-alfa
  • Hepatitis delta virus
    • 96-week follow-up of immediate vs delayed bulevirtide
    • Off-treatment response for lonafarnib + ritonavir ± pegIFN-alfa
    • Safety and efficacy outcomes with siRNA JNJ-3989 + nucleos(t)ide analogue
  • Hepatitis C virus
    • Collaborative service at opiate substitution treatment clinic to improve linkage to care in Ireland
    • Nurse-led test-and-treat program to increase screening and diagnosis at female prisons in the United Kingdom
    • FIND-C study using machine learning to improve screening-to-diagnosis ratio using clinical factors and social determinants of health